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Abstract
Background: Conventional serological tests, using total soluble proteins or a cocktail of recombinant proteins from
T. cruzi as antigens, are highly sensitive for Chagas disease diagnosis. This type of tests, however, does not seem to
be reliable tools for short- and medium-term monitoring of the evolution of patients after antiparasitic treatment.
The aim of the present study was to search for immunological markers that could be altered in the sera from
Chagas disease patients after benznidazole treatment, and therefore have a potential predictive diagnostic value.
Methods: We analyzed the reactivity of sera from chagasic patients during different clinical phases of the disease
against a series of immunodominant antigens, known as KMP11, PFR2, HSP70 and Tgp63. The reactivity of the sera
from 46 adult Chronic Chagas disease patients living in a non-endemic country without vector transmission of T.
cruzi (15 patients in the indeterminate stage, 16 in the cardiomiopathy stage and 16 in the digestive stage) and 22
control sera from non-infected subjects was analyzed. We also analyzed the response dynamics of sera from those
patients who had been treated with benznidazole.
Results: Regardless of the stage of the sickness, the sera from chagasic patients reacted against KMP11, HSP70, PFR2
and Tgp63 recombinant proteins with statistical significance relative to the reactivity against the same antigens by
the sera from healthy donors, patients with autoimmune diseases or patients suffering from tuberculosis, leprosy or
malaria. Shortly after benznidazole treatment, a statistically significant decrease in reactivity against KMP11, HSP70
and PFR2 was observed (six or nine month). It was also observed that, following benznidazole treatment, the
differential reactivity against these antigens co-relates with the clinical status of the patients.
Conclusions: The recombinant antigens KMP11, PFR2, Tgp63 and HSP70 are recognized by Chagas disease
patients’ sera at any clinical stage of the disease. Shortly after benznidazole treatment, a drop in reactivity against
three of these antigens is produced in an antigen-specific manner. Most likely, analysis of the reactivity against
these recombinant antigens may be useful for monitoring the effectiveness of benznidazole treatment.
Background
Chagas disease or American trypanosomiasis is a com-
plex anthropozoonosis caused by the flagellate proto-
zoan parasite Trypanosoma cruzi.T h i ss i c k n e s sa f f e c t s
around 8 million people in Latin-America despite the
intensive programs implemented to control the illness-
transmitting vectors [1-3]. In addition, the increasing
number of migrants from Latin-American countries has
globally spread the T. cruzi infection to non-endemic
areas [4,5]. Nowadays, other ways of infection such as
congenital transmission, blood transfusion and organ
transplantation are becoming prevalent and relevant
from a public health point of view in both endemic and
non-endemic countries [6].
The disease passes through various different clinical
stages. The parasite can be visualized in the blood
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PCR in the chronic stages of the disease. In absence of
treatment, the acute phase is followed by an indetermi-
nate stage in which the parasites are present into speci-
fic tissues [7]. In 30% of patients, the infection leads to
a symptomatic chronic phase. Despite low mortality
during this symptomatic stage, serious cardiac and/or
digestive alterations are present [7,8]. Arrhythmias, elec-
trocardiographic abnormalities together with cardiome-
galy and/or systolic dysfunction may appear when there
is cardiac damage [9,10]. Megaesophagus or megacolon
are indicative of gastrointestinal damage and, although
these clinical manifestations are usually not highly
severe, they are associated to morbidity [11].
Anti-trypanosomal treatment is strongly recom-
mended for all cases of the acute, congenital and reacti-
vated infection of T. cruzi, and for the treatment of
young chronic patients [3]. However, its efficacy for
treatment of adult patients in the chronic phase of the
disease is under consideration [12,13]. New drugs are
being currently examined, some now in the advanced
stages of development [14].
At present, the most widely used serological tests for
Chagas disease diagnosis are based on homogenates of
total parasite proteins or combinations of recombinant
proteins as antigens [15-17]. Although all these techni-
ques are very sensitive for the diagnosis of Chagas dis-
ease [18], the evaluation of the evolution of the patients
under and following treatment is ambiguous since some
T. cruzi antibodies are long lasting [19] and a significant
seroconversion occurs only several years post treatment
[11,20]. Thus, conventional serological tests are not use-
ful for short- and medium-term post-treatment moni-
toring as they do not allow early recognition of a
therapeutic failure [21-23]. Consequently, reliable tools
for the evaluation of the therapeutic efficacy of the
drugs are needed.
The aim of the present study was to search for immu-
nological markers, against which the reactivity of sera
from Chagas disease patients could be modified by
benznidazole treatment, thus providing potential predic-
tive diagnostic value.
Methods
Human sera
Serum samples from 46 adult Chagas disease patients
and 22 control sera from healthy adult donors (HD)
were collected at the Hospital Clínic in Barcelona and
Hospital Virgen de la Arrixaca in Murcia (Spain). All
patients and healthy donors came from endemic areas
and were Spanish residents in whom T. cruzi reinfection
does not occur (Table 1). The patients included in the
study had never received benznidazole/nifurtimox
treatment.
Following WHO criteria, Chagas disease diagnosis was
made using two different commercial serological tests
(ELISA-Bioelisa Chagas, Biokit (Barcelona, Spain) and
IFI-Inmunofluor Chagas, Biocientífica, Argentina) pre-
vious to inclusion. All patients were at the chronic stage
of the disease and were classified into three main cate-
gories. Chagasic patients were considered at the Indeter-
minate stage (IND, n = 15) when there was no evidence
of cardiac or gastrointestinal disorders; the Chronic
Chagas Cardiomiopathy stage (CCC, n = 16) was catalo-
gued into G1 to G3 stages of Kuschnir classification
[24] according to clinical criteria and radiological, elec-
trocardiographic and echocardiography analyses; the
digestive stage (DIG, n = 15) was established when
mega-esophagus and/or megacolon abnormalities in the
gastrointestinal tract were detected by barium enema
and esophagogram. All IND and CCC and 10 DIG cha-
gasic patients were treated with benznidazole (5 mg/kg/
day for 60 days) and clinically followed up during the
period of this study. No changes in the clinical status of
the patients were observed during this follow-up period.
Blood samples were collected prior to treatment
administration (T0) and at regular time intervals of
three (T1), six (T2) and nine (T3) months post-treat-
ment. Aliquots of the sera were stored at -80°C in 50%
glycerol.
Serum samples from patients with different autoim-
mune diseases or patients suffering an infectious disease
other than Chagas disease were also included in this
study. Sera were collected from 15 patients suffering
autoimmune diseases from non-endemic areas: Systemic
Lupus Erythematosus (SLE) (n = 6), celiac disease (n =
4) and rheumatoid arthritis (n = 5). Sera were collected
from Hospital de la Santa Creu i Sant Pau (Barcelona)
as well as 24 serum samples from patients suffering
leprosy (n = 8), tuberculosis (n = 8) and malaria (n = 8)
from the Institute of Tropical Medicine (Caracas-
Venezuela).
Ethical considerations
The protocols were approved by the Ethical Committees
at Hospital Clínic, Hospital Virgen de la Arrixaca and
Consejo Superior de Investigaciones Científicas (Spain).
A signed informed consent was obtained from all indivi-
duals prior to their inclusion in the study.
Gene cloning and protein purification
The DNA sequence coding for the gp63 protein frag-
ment (Tgp63) [25] was amplified by PCR using Leish-
mania infantum genomic DNA as template and
Q5’gp63Li (5’CAAGGGTACCGGAACGACCTGCCAG
3’)a n dQ 3 ’gp63Li (5’CTGAAAGCTTACCCCGGCCC-
CACG 3’) primers which bear KpnIa n dHindIII restric-
tion sites, respectively. The 483 nucleotide fragment
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which is implicated in the molecular interaction with
the macrophage surface molecules [26] was digested
with KpnIa n dHindIII enzymes and subcloned into the
pQE30 plasmid (Qiagen, California, USA) digested with
the same enzymes.
Tgp63 recombinant protein was overexpressed in the
Escherichia coli M15 strain by addition of 0.1 mM iso-
propyl-beta-D-thiogalactopyranoside (IPTG) and grown
at 37°C for 3 h. Proteins were solubilized in resuspension
buffer (0.3 M NaCl and 50 mM NaH2PO4, 1 mM phenyl
methyl sulfonyl fluoride, pH 8) by sonication. The Tgp63
protein was bound overnight to the Ni
2+ NTA resin (Qia-
gen, California, USA) at 4°C with gentle shaking. After
extensive washing with resuspension buffer at pH from 8
to 6, the Tgp63 protein was subsequently eluted with the
same buffer at pH 4-5. T. cruzi KMP11 [27], HSP70 [28].
PFR2 [29] recombinant proteins were overexpressed in
bacteria and purified as described previously.
To obtain soluble total protein extract (STcA), T. cruzi
trypomastigote forms (Y strain) obtained from T. cruzi
infected mice were used to infect monolayers of LLC-MK2
fibroblast cells at parasite:cell ratio of 5:1 for 12 hours. Cell
cultures were washed to remove the parasites that were not
able to infect cells and incubated at 37°C in an atmosphere
containing 5% CO2. Amastigote/trypomastigote parasites
(ratio 3/1) were recovered from infected-culture superna-
tants and washed in PBS. Parasites were resuspended in
lysis buffer (50 mM Tris-HCl at pH 7.4, 0.05% NP-40, 50
mM NaCl, 1 mM PMSF, 1 μg/mL leupeptin) and soni-
cated. Soluble protein extracts were obtained after centrifu-
gation at 10,000 rpm for 20 min at 4°C.
ELISA measurement
ELISA tests were carried out as described in Thomas et
al. [30]. Briefly, ELISA 8-well strips (Nunc, Roskilde,
Denmark) were coated with 0.5 μg of protein and stored
in a dry atmosphere at -20°C until use. Subsequently, the
wells were washed twice with 200 μL of PBS-0.05%
Tween-20 and incubated for one hour with blocking
solution (5% nonfat dried milk powder in PBS).
Afterwards, the antigen-coated wells were incubated with
patient sera at 1/800 dilution (for HSP70, PFR2 and
Tgp63), 1/3,200 (for KMP11), and 1/6,400 for STcA, for
two hours at 37°C. Selection of serum dilutions was
established for individual antigens using a pool of sera
from 6 patients with Chagas disease who lived in ende-
mic areas. The dilution at which each antigen was
assayed corresponds to the linear part of the curve after a
titration analysis. As a secondary antibody, an affinity-
isolated goat anti-human IgG antibody peroxidase-conju-
gated (Biosource, New York, USA) at dilution 1:2,000
was used. The reaction was incubated for 1 h at 37°C.
After washing, the reaction was developed using ortho-
phenylenediamine for 5 minutes in the dark at room
temperature. The reaction was stopped by addition of 2N
sulfuric acid and the absorbance was measured at 492
nm. Serum samples were assayed in triplicate and at two
dilutions. Positive and negative control sera were
included in all plates. The cut-off values represent the
mean value of the reactivity of a pool of sera from healthy
donors (sensitivity) or from patients with autoimmune or
infectious diseases other than Chagas disease (specificity),
plus two standard deviations.
Statistical analysis
Statistical analyses were performed using the SPSS sta-
tistical package version 15.0 (Spss Inc., Chicago Illinois).
The Mann Withney U test was used to carry out com-
parisons among groups of patients. The Wilcoxon test
was used to study post-treatment evolution. Statistical
significance was assigned at a value of p ≤ 0.05. Pearson
correlation analyses were used to evaluate the correla-
tion between reactivity levels against KMP11, HSP70,
PFR2 and Tgp63. Significant correlation was assigned at
a value of p ≤ 0.05.
Results and Discussion
Recognition of KMP11, HSP70, PFR2, Tgp63, and STcA by
sera from chagasic patients
The T. cruzi KMP11, HSP70, and PFR2 proteins, and
the L. infantum Tgp63 fragment (Figure 1, lanes 1-4)
Table 1 Characteristics of the population under study
SUBJECTS
a MEAN AGE
IN YEARS
(range)
MALE (%) FEMALE (%) ORIGIN (%)
HD (n = 22) 31.5 (18-54) 14 (63.6) 8 (36.4) 15 Bolivia (70); 7 Ecuador (30)
IND (n = 15) 33.5 (22-56) 14 (93.3) 1 (6.67) 13 Bolivia (86.6); 1 Brasil (6.7);
1 Paraguay (6.7)
CCC (n = 16) 44.1 (27-68) 9 (56.3) 7 (43.7) 14 Bolivia (87.5); 1 Brasil (6.3);
1 Argentina (6.3)
DIG (n = 15) 39.1 (24-56) 10 (66.6) 5 (33.4) 14 Bolivia (93.3); 1 Argentina (6,7)
a HD: Healthy donors. IND: Chronic chagasic patients at indeterminate clinical form of the disease. CCC: Chronic cardiac chagasic patients. DIG: Chronic chagasic
patients with abnormalities in the gastrointestinal track
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because in previous reports [26,30,31] and in prelimin-
ary laboratory screening they proved to be immunodo-
minant antigens in chagasic patients. For comparison, a
T. cruzi total soluble protein extract (STcA) (Figure 1,
lane 5) was also included in the study. As shown in Fig-
ure 2A, the KMP11, HSP70, PFR2 and Tgp63 recombi-
nant proteins are recognized with statistical significance
b yt h es e r af r o mc h a g a s i cp a t i e n t s( n=4 6 )r e l a t i v et o
that from healthy donors (HD, n = 22). Furthermore,
these antigens do not react with sera from patients with
autoimmune diseases (SLE, celiac disease and rheuma-
toid arthritis) (AI, n = 15) or patients suffering from
tuberculosis, leprosy or malaria (Inf, n = 24). However,
it is worth mentioning that the sera from patients with
leishmaniosis recognize Tgp63 and KMP11 [30,32].
Thus, the specificity and sensitivity is 85% and 90% for
KMP11, 85% and 90% for HSP70, 92% and 75% for
PFR2 and 70% and 30% for Tgp63.
When the reactivity data were analyzed in relation to
the clinical stage of Chagas’ disease, it was observed
(Figure 2B) that the sera from IND, CCC and DIG
groups recognize with statistical significance the
KMP11, HSP70, PFR2 recombinant proteins when com-
pared with healthy donors (HD). These antigens are
recognized by sera from chagasic patients regardless of
the stage of the illness. In DIG patients, the reactivity
level against Tgp63 was also higher than that detected
in the sera from HD. The results presented suggest that
these antigens could be used to detect T. cruzi infection
in any clinical form of Chagas disease. It has been
recently described that the sera from CCC and IND
chagasic patients living in endemic areas recognize the
T. cruzi KMP11 and Trypanosoma rangeli HSP70 [33].
In order to determine whether there is any correlation
between the reactivity detected in the sera from each
one of the chagasic patient against the antigens tested, a
paired correlation analysis was carried out. A statistically
significant correlation was observed between reactivity
against KMP11 and HSP70, with values of r = 0.518 (p
= 0.048) in CCC patients and r = 0,632 (p < 0.02) in
patients with digestive clinical manifestations. Moreover,
a statistically significant correlation was also observed in
DIG patients in their response against KMP11 and
PFR2, with values r = 0.719 (p < = 0.005). No correla-
tion was observed in the IND patients between any of
the antigens under study. This differential reactivity
M W  (kDa)  1      2       3       4        5
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21.5
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Figure 1 Purified recombinant antigens and soluble proteins
from T. cruzi. The KMP11 (lane 1), HSP70 (lane 2), Tgp63 (lane 3),
PFR2 (lane 4) recombinant proteins and the total protein lysate,
STcA (lane 5) were resolved in a 12% SDS-PAGE gel and visualized
by Coomassie brilliant blue staining.
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Figure 2 IgG antibodies specific to KMP11, HSP70, PFR2 and
Tgp63 parasite recombinant antigens. The level of IgG
antibodies was measured by ELISA. Data are expressed as optical
density (O.D.) values. Statistically significant differences (p < 0.05) are
indicated. O.D. values of the percentage of patients comprised
between 25% and 75% are represented as vertical boxes and the
corresponding medians as a horizontal line inside the boxes. Error
bars represent 10% and 90% intervals (A) Sera from 22 healthy
donors (HD), 46 non-treated chagasic patients (Ch), 15 patients with
autoimmune disease (AI) and 24 patients with an infectious disease
other than Chagas disease (Inf). (B) Sera from 22 healthy donors
(HD), 15 indeterminate (IND), 16 cardiac (CCC) and 15 digestive
(DIG) chagasic patients.
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tiated exposure of each one of the antigens to the host
immune system due to their specific location in the
parasite [27,34] or, alternatively, to the ability of the
immune system to recognize antigens depending on the
stage of the illness. Tarleton’s group has recently
described the recognition of a panel of 16 T. cruzi pro-
teins by sera from Chagas disease patients living in
endemic areas, reporting that the antigens recognition
pattern is specific for each serum [23].
Changes in antigen-specific responses after patient’
benznidazole treatment
To address the effect of a 60-day course of benznidazole
treatment in the pattern of recognition of the above
mentioned antigens, serum samples from a total of 35
chagasic patients (15 IND, 10 CCC and 10 DIG) were
analyzed before (T0) and after benznidazole administra-
tion at regular time intervals (3, 6 and 9 months) T1,
T2 and T3, respectively. The follow-up of the serological
response could only be carried out in 35 patients out of
the 46 initially enrolled because 11 of them changed
their residence and moved to another city or returned
to their countries. Interestingly, a short term decrease in
reactivity against KMP11, HSP70 and PFR2 was
observed post-treatment. The decrease in reactivity
against KMP11 occurred six months and nine months
against PFR2 and HSP70 (Figure 3A). The drop in reac-
tivity remained or continued decreasing during the post-
treatment follow-up period (two years). A further
decrease in reactivity was observed in 67%, 50% and
34% of the patients for KMP11, HSP70 and PFR2,
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Figure 3 Effect of benznidazole treatment in antigen recognition. The reactivity of sera from 25 patients with Chagas disease (A),1 5
patients in the indeterminate (IND) stage (B), 10 in the chronic and cardiac phase (CCC) (C), 8 patients in the early chronic cardiac stage of the
disease (G1 and G2) (D) and 10 digestive chagasic patients (E) were assayed by ELISA against KMP11, HSP70, PFR2, Tgp63 and STcA before
benznidazole treatment (T0), and 3 (T1), 6 (T2), and 9 (T3) months post-treatment for A, B, C and D and 9 (T3) months post-treatment for E.
Data are expressed as optical density (O.D.) values. The data are the result of a statistical analysis of the median of the differences in antigen-
specific recognition that were separately analyzed in each treated patient at the different post-treatment times relative to T0. The p values were
obtained by the Wilcoxon matched pair test and significant differences (p < 0.05) are indicated.
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drop in reactivity was observed against STcAa n d
Tgp63. Thus, at a humoral response level, analysis of
the reactivity against these antigens is likely to be a use-
ful tool for evaluating the influence of benznidazole
treatment. One of the challenges in Chagas disease is
the lack of early markers in the cure or progression of
the disease after parasitic treatment. The use of whole
parasite lysates or specific recombinant antigen mixture
hardly ever provides conclusive results in short- or med-
ium-term follow-up of Chagas patients under treatment
[9,22,35]. PCR could be useful in identifying treatment
failure in patients with positive detection of T. cruzi
DNA in their blood stream but does not prove treat-
ment success since even repeated negative PCR results
do not necessarily indicate parasitological cure [3]. In
fact there is no direct correlation between a negative
PCR result and T. cruzi infection [3].
W h e nt h er e a c t i v i t ya g a i n s tt h er e c o m b i n a n ta n t i g e n s
was analyzed taking into consideration the stage of the dis-
ease of the treated patients, variations in reactivity against
the individual antigens were observed. Thus in patients
grouped as being in the indeterminate stage, a statistically
significant decrease in reactivity against KMP11 was only
observed 6 months post-treatment (Figure 3B). However, in
chronic cardiac patients, a statistically significant decrease
in reactivity was detected against HSP70 and PFR2 (Figure
3C). This fall in anti-PFR2 and anti-HSP70 specific anti-
body level was detected 3 and 6 months post-treatment,
respectively. When the reactivity of the sera from chronic
cardiac patients was evaluated in detail, a decrease in the
recognition of KMP11, in addition to PFR2 and HSP70,
was observed in patients in the early phase of the cardio-
myopathy (G1 and G2 stages) (Figure 3D). Nonetheless, a
statistically significant drop in reactivity against the antigens
was not observed in the chronic cardiac chagasic patients in
the advanced stage of the disease (G3). In DIG patients, a
statistically significant decrease in reactivity against PFR2
was only observed 9 months post-treatment (Figure 3E).
These data indicate that the short-term decrease in recog-
nition of single and specific parasite antigens observed after
benznidazole treatment are differentially regulated depend-
ing on the clinical stage of the disease. A statistically signifi-
cant drop in reactivity against the STcA was not observed
in any patient group (Figure 3A-E).
The observed decrease in the antigen specific humoral
responses in sera of patients following benznidazole
treatment could be interpreted as the result of a balance
between several effects in which the immune compe-
tence of the infected host is a factor to be considered.
Most likely, benznidazole treatment could reduce the
parasite load and thus, also reduce the amount of anti-
gen necessary to activate an antibody response as has
been recently suggested [36]. In fact, there are already
data indicating that benznidazole treatment in experi-
mentally infected mice induces a decrease in the percen-
tage of circulating parasites [37,38]. It is also probable
that the antibodies generated against KMP11, PFR2 and
HSP70 antigens of the parasite have a short half-life and
therefore, are likely to be influenced by the treatment.
Although further studies testing sera from a higher
number of chagasic patients from endemic areas could
be necessary to draw conclusive data for an immunolo-
gical clinical follow-up, the results presented here show
that the detection of reactivity against different and spe-
cific antigens may be useful for monitoring the effective-
ness of benznidazole treatment.
Conclusions
This study shows that benznidazol treatment in chagasic
patients alters the humoral response pattern against spe-
cific antigens in a sickness status dependent manner.
This paper describes a useful serological marker system
for monitoring the effectiveness of drug treatment in
Chagas disease, and a tool that may well allow early
detection of therapeutic failure.
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